In another study, a multiplexed, noninvasive continuous monitoring platform was engineered for tracking inflammatory markers, particularly C‐reactive protein (CRP) and interleukin‐1β (IL‐1β) as a method to evaluate therapeutic efficacy in patients with inflammatory bowel disease.[119] This biosensor construct includes two‐electrode system integrated into a smartwatch‐like wearable device and employs EIS for real‐time monitoring of both CRP and IL‐1β in human sweat. The gene discussed is IL1B; the disease is inflammatory bowel disease.